ENDPOINTS

FDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale

Plus, news about CytomX, Valneva, Lenz and Lotus Pharmaceutical:

May 12, 2025 - 15:36
 0
FDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale
Plus, news about CytomX, Valneva, Lenz and Lotus Pharmaceutical:
Read More

Tags:

Previous Article

How AI, Analytics, and Collaboration Can Solve Specialty Drug Spending Challenges

Next Article

Climate Policy Outlook: 4 stories to follow this week

Related Posts

Unity lays off 'all' workers; Novo to get FDA decision on oral Wegovy this year

Unity lays off 'all' workers; Novo to get FDA decision ...

May 5, 2025  0

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

AstraZeneca reports Phase 3 win for Imfinzi; Roche to b...

May 9, 2025  0

Theriva’s oncolytic virus succeeds in pancreatic cancer study, but stock falls

Theriva’s oncolytic virus succeeds in pancreatic cancer...

May 7, 2025  0